Bacterial Conjunctivitis Treatment Market: By Infection; By Antibacterial Class; By Method & By Geography - Forecast 2016-2021

  • ID: 3973935
  • Report
  • 135 pages
  • IndustryARC
1 of 3
Bacterial conjunctivitis is a serious eye infection caused by several types of bacteria. Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. Herbal medicines are also being developed for better treatment measures. This report encompasses analysis of the global market for bacterial conjunctivitis treatment on the basis of treatment methods, infection type, antibacterial class and geography.

The bacterial conjunctivitis treatment market is classified on the basis of methods into:

Eye drops
The prescription and usage of the aforementioned medications depends on severity of infection and even the cause. Advancements in research on microbiology have been supporting the pharmaceutical companies to develop and launch various anti-bacterial drugs that are useful for effective treatment of bacterial conjunctivitis.

North America leads the market with a share of XX% followed by APAC. APAC is set to be the fastest growing market for the coming years, growing at a CAGR of XX%. Introduction of new formulations and increasing reach of healthcare are the major drivers in APAC region. China and India provides huge growth opportunities for the market players.

The key players in the bacterial conjunctivitis treatment market include:

Akorn, Inc.

Pfizer, Inc.

Merck & Co.

Novartis AG
Bayer AG
The estimates and forecasts have been derived based on various inputs from primary and secondary sources. Secondary sources such as articles, whitepapers, journals and other has helped to deliver an extensive analysis in this report. To enhance the accuracy of the estimates, the data has been validated by conducting interviews with industry experts. This report on the bacterial conjunctivitis treatment market identifies many such insights, market share analysis and innovation, besides providing a detailed analysis of the key players, distributors and growth rate of the market.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Bacterial Conjunctivitis Treatment Market Overview
1.1. Introduction
1.2. Classification

2. Executive Summary

3. Bacterial Conjunctivitis Treatment Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. Patent Analysis
3.2.3. Financials of Key Players

4. Bacterial Conjunctivitis Treatment Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Market
4.4.1. Suppliers Power
4.4.2. Bargaining Power of Buyer
4.4.3. Threat from New Entrants
4.4.4. Threats from Substitutes
4.4.5. Degree of Competition

5. Bacterial Conjunctivitis Treatment Market – Strategic Analysis
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis

6. Bacterial Conjunctivitis Treatment Market– By Infection Type
6.1. Neonatal Conjunctivitis
6.2. Adult Gonococcal Conjunctivitis
6.3. Trachoma

7. Bacterial Conjunctivitis Treatment Market– By Antibacterial Class
7.1. Fluoroquinolones
7.2. Aminoglycosides
7.3. Macrolides
7.4. Others

8. Bacterial Conjunctivitis Treatment Market– By Method
8.1. Ointments
8.2. Eye Drops
8.3. Drugs

9. Bacterial Conjunctivitis Treatment Market-Geographic Analysis
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. U.K.
9.3.2. Germany
9.3.3. France
9.3.4. Italy
9.3.5. Rest of Europe
9.4. APAC
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of APAC
9.5. RoW
9.5.1. South America
9.5.2. Middle East
9.5.3. Africa

10. Market Entropy

11. Company Profiles (Overview, Financials, Developments and Product Portfolio)
11.1. Bayer AG
11.2. Hoffman-LaRoche, Ltd.
11.3. Merck & Co.
11.4. Novartis AG
11.5. Pfizer, Inc.
11.6. Akorn, Inc.
11.7. Allergan, Inc.
11.8. Perrigo Company plc
11.9. Santen Pharmaceutical Co., Ltd.
11.10. Valeant Pharmaceuticals International, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown